Biotechnology

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians. Australia could save $25.2 billion in CKD-related costs and more than...

2025-06-06 23:00 2819

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of safe and efficient cargo ...

2025-06-06 18:17 3515

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy

* Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early tr...

2025-06-06 16:12 2455

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as  a globalleader in the development and  production of pharmaceut...

2025-06-06 14:00 2364

Kelun-Biotech Announces Approximately US$250 Million Placement

CHENGDU, China, June 6, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of t...

2025-06-06 11:04 4311

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®

MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the  International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a h...

2025-06-05 20:00 2264

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Car...

2025-06-05 09:04 3283

Proto Axiom and St Vincent's Curran Foundation join forces to host Australia's largest medical pitch day

SYDNEY, June 5, 2025 /PRNewswire/ -- Proto Axiom, Australia's leading biotech incubator, and St Vincent's Curran Foundation unite to launch Challenger Pitch for Health, the nation's largest medical and biotech pitch event, in Sydney in March 2026. Challenger Pitch for Health will award $500,000 ...

2025-06-05 07:55 2036

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The a...

2025-06-04 20:00 2799

Elpis Biopharmaceuticals and Singapore General Hospital Enter Research Collaboration Agreement to Develop Next Generation Allogeneic CAR Technologies

Agreement focuses on advancing armored and bi-specific CAR-γδTs for AML and multiple myeloma LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announc...

2025-06-04 19:00 2529

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific re...

2025-06-04 06:30 3960

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell analysis and sorting technologies, today announced the pre-commercial launch of MorphoScan Cloud, its new cloud-based platform designed for flexible data access, faster processing, and advanc...

2025-06-03 23:34 2102

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

* EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6.  * The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of p...

2025-06-03 14:00 2733

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical iso...

2025-06-02 09:00 2937

Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience

New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials  SINGAPORE, June 2, 2025 /PRNewswire/ -- Medidata , a Dassault Systèmes brand and leading provider of clinical...

2025-06-02 09:00 2274

Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology

DA NANG, Vietnam, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions , a pioneer in AI-driven precision oncology hosted  K-CONNECT APAC 2025 , a pivotal summit unitingover 100 distinguished oncologists and molecular biologis...

2025-05-31 10:16 4523

Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration

JOHNSON CITY, Tenn., May 30, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain laboratory service system covering...

2025-05-30 05:05 2355

Dx&Vx Accelerates Development of Universal COVID-19 Vaccine

* Emerging as a next-generation vaccine amidst global resurgence of COVID-19 * Expanding v arious pipelines other than universal COVID vaccine SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development progr...

2025-05-29 21:03 2434

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

SHANGHAI, May 29, 2025 /PRNewswire/ -- Rona Therapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Scientific Sessions. Preclinical studies revealed that the t...

2025-05-29 20:00 2937

tHIS ASEAN 2025 to Debut in Kuala Lumpur, Uniting Southeast Asia's Healthcare Powerhouses

KUALA LUMPUR, Malaysia, May 29, 2025 /PRNewswire/ -- The Health Industry Series - ASEAN (tHIS ASEAN 2025), a groundbreaking event aimed at integrating healthcare resources across Southeast Asia, is set to take place in Kuala Lumpur during June 9-11. Co-located with the APHM International Healthca...

2025-05-29 19:22 2913
1 ... 22232425262728 ... 186

Week's Top Stories